

Supplementary Tables

Table S1: Detailed clinical and pathological characteristics of the discovery cohort

	ID	Age	BMI	Medications	PSA (ng/ml)	Tumour Volume (cc)	pT	ISUP Group	CARPA- S
Low Risk	10863	56	31.7	Nil	7.4	3.3	pT3a	2	3
	10870	61	23.7	Nil	4	0.7	pT2c	2	1
	10814	60	28.4	Nil	4.7	1.6	pT2c	1	0
	10826	65	NR	Nil	12	0.1	pT2a	2	3
	10845	66	32.7	Pantoprazole	6.5	0.5	pT3a	1	2
	10913	66	20.1	Atorvastatin, nizatidine, pantoprazole	1.6	0.1	pT2c	2	1
	10991	68	28.5	Simvastatin, rabeprazole, sertraline	6.1	1.0	pT2c	1	3
	10994	55	26.3	Nil	1.8	0.3	pT2c	2	1
	10998	66	26.9	Rabeprazole	6.8	0.1	pT2a	1	1
	11071	56	33.4	Nil	8	0.2	pT2a	2	4*
High Risk	10922	65	24.3	Paracetamol, ibuprofen	2.7	17.8	pT3b	5	8
	10935	72	28.2	Atorvastatin, perindopril, aspirin	14.2	4.9	pT3a	5	6
	10973	67	23.7	Irbesartan	8.6	6.7	pT3b	5	7
	10976	66	25.0	Nil	6.5	17.8	pT3a	3	6
	10985	72	27.3	Atorvastatin, perindopril	5.4	9.8	pT3a	3	3
	11026	49	30.7	Nil	16	9.9	pT3a	3	7
	11045	67	27.4	Enalapril, candesartan, esomeprazole	6.9	7.4	pT3a	5	7
	11126	59	24.1	Oxazepam	8.1	6.2	pT3b	5	7
	11132	68	25.5	Pred forte eye drops	27	0.7	pT3a	4	9
	11147	69	32.9	Esomeprazole, olmesartan, amlodipine, rosuvastatin, warfarin	6.3	1.4	pT3a	5	5

NR = not recorded. *Positive margin contributing 2 points to the total score.